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In the present study, Form I, Form II and Form III of agomelatine were prepared to
investigate the variability of polymorphs, then the in-vitro in-vivo correlation were
established. The presence of three polymorphs of agomelatine was corroborated through
studies by XRPD, TGA and DSC. All the forms obtained were then subjected to the powder
and intrinsic dissolution tests. The IDR ranked in the order of Form III > Form I > Form II.
Form I and Form III both underwent solvent-mediated phase transformation (SMPT) to
Form II during dissolution and the transition points were 62 and 45 min, respectively.
Pharmacokinetic profiles were acquired after oral administration of tablets, showing that
the ka and AUC0e12 h of Form I, Form II, Form III were 0.58  0.11, 0.34  0.05, 0.74  0.07 h1
and 296.25  49.39, 186.05  45.93, 331.16  54.74 ng*h/ml, respectively. Good linearities
between IDR and ka, IDR and AUC were established, suggesting that the agomelatine
polymorphic forms with faster dissolution rates in-vitro would increase the rate and extent
of oral absorption in-vivo. These results demonstrated that IDR was predictive in esti-
mating the relative bioavailability of agomelatine polymorphic forms.
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rights reserved.1. Introduction resynchronization of circadian rhythms and antidepressantAgomelatine (N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide),
is a novel antidepressant developed by Servier Laboratories
[1]. It represents the only MT1/MT2 melatonergic receptor
agonist and 5-HT2C antagonist available, shown to induceoad, Guangzhou Higher
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manax; Servier) was granted marketing authorization in 2009
for the treatment of major depression in Europe and become
the first approved antidepressant to incorporate a non-
monoaminergic mechanism of action [1,5].
After oral administration there is rapid and high absorp-
tion of agomelatine with low absolute bioavailability (<5% at
the therapeutic oral dose) and substantial interindividual
variability [6]. Up to now, at least six polymorphs as well as
other solvates are known for agomelatine [7]. However, little
information is available about their in-vitro physicochemical
properties such as the dissolution behavior. In addition, the
effect of agomelatine polymorphism on its bioavailability and
the relationship between the in-vitro dissolution properties
and in-vivo pharmacokinetics of agomelatine polymorphs are
not determined.
Polymorphism is defined as the ability of a compound to
exist in two or more crystalline phases with different ar-
rangements and/or conformations of the molecule in the
crystal lattice [8]. These individual crystal phases can exhibit
differences in physicochemical properties, such as stability,
dissolution rate, and solubility, which may affect drug man-
ufacturability and quality/in-vivo performance [9]. The phe-
nomenon of polymorphism is very common among
pharmaceutical substances and has been widely reported in
the literature [8e13]. Thorough investigation and character-
ization of a polymorphic drug substance are recognized as an
essential part of drug development [14].
For this reason, the following objectives were set for this
study: firstly, to investigate the variability of agomelatine
polymorphs by fully characterizing the physicochemical
properties using a variety of approaches (XRPD, DSC, TGA,
solubility, and disc intrinsic dissolution rate); Secondly, to
determine the effects of physicochemical properties of Form I,
Form II and Form III on the plasma level of agomelatine by
performing pharmacokinetic tests on Beagle dogs; Finally, to
establish the correlation between in-vitro properties and in-
vivo absorption.2. Materials and methods
2.1. Materials
Agomelatine (99.9% purity; Korey Pharm Co. Ltd., shanghai,
China) was used without further purification. The original
drug substance employed here was identified to be Form II
exclusively. All organic solvents were HPLC grade. All other
chemicals and reagents were analytical grade. All the solvents
employed were commercially available and used as received
without further purification.
2.2. Preparation of agomelatine polymorphs
In search of all possible polymorphs of agomelatine, a variety
of preparation methods, including solvent cooling, solvent
evaporation, melt crystallization, anti-solvent and spray dry-
ing method were tried in our study. Eventually, another two
distinct polymorphic forms were obtained, which were iden-
tified as Form I and Form III in accordance with the findingsdisclosed in the US patents [7,15,16]. In order to get crystalline
forms with high purity reliably and reproducibly, the
following procedure was used:
 Form I: 1 g agomelatine bulk powder suspending in ethylene
glycol was heated to 60 C. The hot solution was filtered to
remove undissolved nuclei and then cooled to room tem-
perature. The filtrate was dropwise to ice-water mixture
stirring with a magnetic stirrer. The precipitated crystals
were collected on a filter and dried at 35 C.
 Form III: 1 g agomelatine bulk powder was heated at 110 C
in an oven until themeltingwas completed, and then slowly
cooled until crystallization [16].
The received crystals were all stored in a desiccator at
room temperature and identified by XRPD, DSC and TGA.
2.3. Identification of agomelatine polymorphs
2.3.1. X-ray powder diffraction (XRPD)
XRPD patterns were recorded at room temperature on a
Rigaku Powder X-ray diffraction system (Model D/MAX-2200
Ultima/PC, Japan) with Ni-filtered Cu-Ka radiation powered
at 40 kV and 30 mA. The samples were packed into a quartz
cell of 0.2 cm deep and analyzed over an angular range from 3
to 40 in continuous scanmode by using a step size of 0.02and
scan rate of 10/min.
2.3.2. Differential scanning calorimetry (DSC) and
thermogravimetric analysis (TGA)
DSC analysis was performed by using a DSC Q2000 (TA In-
struments, USA) with data analysis via a thermal analyzer
(Universal Analysis 2000, TA Instruments, USA). TGA were
determined by using the NETZSCH TGA system (STA 409 PC)
operatingwith version 6.1 Stare software. Approximately 5mg
samples were weighed (MS105DU microbalance, Mettler
Toledo, Switzerland) in loosely covered aluminum pans and
scanned from 25 C to 120 C at the heating rate of 10 C/min
with the nitrogen gas flow rate of 50 ml/min. The calorimeter
was calibrated by using ultrapure indium (99.999%, melting
point 156.61 C, enthalpy of fusion 28.54 J/g) as standard. DSC
and TGA measurements were both conducted in triplicate.
2.4. Dissolution studies
2.4.1. Dissolution studies by the powder dispersed method
The dissolution behaviors of agomelatine crystalline solids in
the 0.1 M HCl were carried out by using a USP type II (paddle)
apparatus (ZRS-8G, Tianjin Tianda Tianfa Technology Co., Ltd,
China) by the dispersed method. All crystalline powder was
sieved through a 100-mesh screen to provide samples with
approximate particle size ranges of 150e250 mm. Approxi-
mately 350mg sampleswere added to the dissolutionmedium
of 200 ml that maintained at 37  0.5 C and the paddle stirred
at 100 rpm. Samples of 2.0 ml were withdrawn (with
replacement) at predetermined time points up to 72 h and
filtered through a 0.22 mm Nylon syringe filter. Subsequently
they were diluted appropriately and analyzed by an HPLC
system consisting of a pump (L-2130, Hitachi, Japan), an
autosampler (L-2200, Hitachi, Japan) and a UV detector
a s i a n j o u rn a l o f p h a rm a c e u t i c a l s c i e n c e s 8 ( 2 0 1 3 ) 1 8 1e1 9 0 183(L2400, Hitachi, Japan). The conditions of chromatographic
analysis were as follows: Mobile phase: methanol: water
(70:30,v:v); flow rate: 1 ml/min; column: Diamonsil C18
(200 mm  4.6 mm, 5 mm, DIKMA) at 40 C; detection wave-
length: 230 nm; injection volume: 10 ml. Solubility measure-
ments were performed in triplicate. The residual solids after
72 h were characterized by XRPD.
2.4.2. Disc intrinsic dissolution rate （DIDR）
The intrinsic dissolution rates of agomelatine were measured
by the stationary disk method [17] by using drug dissolution
apparatus (RC-1, guoming, China). Studies were performed in
0.1 M HCl at 37  0.5 C. Drug discs (d ¼ 0.4 cm) were made by
compressing 50 mg agomelatine powder in a stainless steel
die using a hydraulic press (speecac) at a pressure of 0.5 ton for
1 min. It was confirmed by the XRPD analysis that no poly-
morphic transition took place during the disc preparation for
any sample. The drug pellet, while inside the die, was placed
at the bottom of the dissolution vessel. The pellet surface that
was flushed against the surface of the die faced upwards. The
opposite surface was sealed from the dissolution medium
with wax. The distance between the bottom of the paddle and
the top surface of the pellet was fixed at 2.0 cm. With the
paddle stirring at 100 rpm, 300 ml of the dissolution medium
that was preconditioned to 37 Cwas poured carefully into the
dissolution vessel at the start of the experiment. The disso-
lution medium was continuously circulated through a flow
cell using a peristaltic pump (BT100-2J, longerpump, China)
and the concentration of agomelatine was analyzed every 60 s
by using UV spectrophotometry (UV2600, Techcomp, China) at
l ¼ 230 nm. The sink conditions were maintained during the
entire dissolution experiment. Dissolution tests were carried
out in triplicate.
2.5. Pharmacokinetic (PK) study in dogs
2.5.1. Animal experiments
Pharmacokinetic studies were performed on six beagle dogs
by using a cross-over method. The animals (15  2 kg) were
supplied by the Kangda Laboratory S&T Co., Ltd. (No.0074144,
Gaoyao, China), and they were randomly divided into three
groups with two subjects each. All experimental procedures
were approved and supervised by the Institutional Animal
Care and Use Committee of Sun Yat-sen University
(Guangzhou, China) and the consent number was IACUC-
2011-0802. In the pharmacokinetic study, after fasting for
16 h with water taken ad libitum, each dogs received single
oral dose of agomelatine tablet of 6.8 mg/kg, respectively. No
food was permitted until a standard meal was served 4 h
after dosing. Blood samples (approximately 2 ml) were
collected from their forelimb veins prior to administration
and at 0.33, 0.66, 1.0, 1.33, 1.66, 2, 2.5, 3, 3.5, 4, 6, 8 and 12 h
after dosing. All the blood samples were centrifuged at
5000 rpm for 10 min at 4 C and the plasma obtained was
stored at 20 C until analysis. A 7-day washout period was
used between doses.
2.5.2. Preparation of tablets
The tablets were prepared by using a single punch tablet press
(ZDY-8, Shanghai Far-east Pharmaceutical Machinery Co.,Ltd., China). According to the weight of the dogs, approxi-
mately 100 mg agomelatine powder of each form was directly
compressed by round punches and dies with a diameter of
6 mm. The hardness was controlled at 7  1 kP.
2.5.3. Preparation of samples
A 100 ml plasma sample was pipetted out into a 1.5 ml
eppendorf tube, then 50 ml of internal standard (glibenclamide,
500 ng/ml) methanol solution and 50 ml methanol were added
to the eppendorf tube. After 30 s of vortex-mixing, 900 ml of
15% (v/v) cyclohexane in ethyl acetate was added, the mixture
was vortexed for 3 min and then put aside for 1 min. The top
organic layer (800 ml) was taken and dried over a stream of
nitrogen. The residue was reconstituted in a mobile phase of
200 ml, followed by vortex-mixing for 1 min. Then 5 ml of it was
injected into the UPLCeMS/MS system for analysis.
2.5.4. Chromatographic and mass spectrometric conditions
Chromatography was performed by using a Waters Acquity
Ultra Performance LC system (Waters, Quattro Premier XE,
USA). Separation was carried out by using a ACQUITY UPLC
BEH Shield RP18 column (2.1 mm  50 mm, 1.7 mm,Waters) at
35 C. Analytes were eluted with an isocratic mobile phase
(0.1% ammoniawater/acetonitrile¼ 35/65, v/v) at a flow rate of
0.3ml/min for 1min. The autosampler was controlled at room
temperature.
Mass spectrometric detection was carried out on a Micro-
mass Quattro Premier API triple-quadrupole tandem mass
spectrometric (Waters) with an electrospray ionization (ESI)
interface. Quantification was performed by using multiple
reaction monitoring (MRM) mode of the ion transitions of m/z
242.0/171.0 for agomelatine and m/z 492.0/367.0 for IS in
negative ionmode. The optimized ionization parameters were
as follows: Capillary voltage 2.5 kV, cone voltage 26 V for
agomelatine and 45 V for IS; Source temperature 120 C, des-
olvation temperature 350 C; Collision energy 13 ev for ago-
melatine and 20 ev for IS. All data were processed by using
Masslynx 4.1 software with a QuanLynx program (Waters).
2.5.5. Pharmacokinetic and statistical analysis
The pharmacokinetic parameters were established through a
two compartment model analysis by using 3p97 pharmaco-
kinetic software (Mathematical Pharmacology Professional
Committee of China, China). Maximum plasma concentration
(Cmax) and time (Tmax) were visually inspected from the
pharmacokinetic profiles, and the area under the concen-
trationetime curve (AUC0e12 h) was calculated by non-
compartmental analysis of the final measurable sample. All
results were presented asmean SD values, and the One-way
ANOVA was performed to determine the significance of dif-
ferences. All calculations were performed using SPSS statis-
tical software program (SPSS 13.0, SPSSInc., USA).
2.6. In-vitro in-vivo correlation (IVIVC) analysis
IVIVC were performed using linear regression analysis (SPSS
13.0, SPSSInc., USA). The pharmacokinetic parameter-
AUC0e12 h and ka were defined as the dependent variable (y)
while the intrinsic dissolution rate was defined as indepen-
dent variables (x).
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3.1. Identification of agomelatine polymorphs
3.1.1. X-ray powder diffraction (XRPD)
XRPD patterns of agomelatine Form I, Form II and Form III
were shown in Fig. 1. Characteristic diffraction peaks were
observed at 2q¼ 11.91, 17.58, 19.59, 19.82 and 25.48 for Form I,
2q ¼ 6.28, 9.25, 12.58, 17.12, 18.58, 18.94 and 22.04 for Form II
and 2q ¼ 10.53, 16.12, 17.80, 23.35 and 24.90 for Form III. All
these forms showed well-resolved diffraction patterns with
distinct peaks characteristic of each specific form corre-
sponding to literature data for agomelatine [7,15,16]. It was
therefore confirmed that Form I, Form II and Form III of ago-
melatine were properly formed.
3.1.2. Differential scanning calorimetry (DSC) and
thermogravimetric analysis (TGA)
As shown in Fig. 2, the DSC thermograms of agomelatine
polymorphic forms were consistent with previous findings,
which indicated a sharp endotherm at 99.08 C for Form I,
109.29 C for Form II and 100.41 C for Form III, respectively
[7,15,16]. The TGA traces were also shown in Fig. 2. No
appreciable weight loss was observed in the TGA traces. Nor
was the characteristic of desolvation or decomposition
recorded, indicating that the forms were anhydrous and
nonsolvated.Fig. 1 e XRPD patterns for agomelatine polymorMany active pharmaceutical ingredient exist in various
polymorphic forms, but generally only some forms can be
obtained in the laboratory and industrial production. In the
search of agomelatine polymorphisms, only three forms of
the six reported polymorphs of agomelatine were obtained. In
consideration of the stability or manufacturability problems,
others were not suitable for further development. Thus only
Form I, Form II and Form III of agomelatine were selected for
further investigations.
3.2. Dissolution studies
To exclude the influence of particle size on the dissolution
behavior, the powder of the three forms was sieved by using
standard mesh sieves to provide samples with approximate
particle size ranges of 150e250 mm.
3.2.1. Dissolution studies by the powder dispersed method
The dissolution behaviors of the individual form determined
by the powder dispersionmethodwere demonstrated in Fig. 3.
In the case of Form II, the maximum concentration was
observed at 60 min and maintained until the end of the
experiment. In contrast, the concentration of Form I and Form
III reached the maximum around 70 min but both decreased
gradually after 72 h. As shown in Table 1, the obtained
maximum concentration of Form I and Form III was 550 and
622 mg/ml while that of Form II was much lower (approxi-
mately 340 mg/ml).phs. (A) Form I, (B) Form II, and (C) Form III.
Fig. 2 e DSC thermograms and TGA traces for agomelatine polymorphs. (A) Form II, (B) Form I, and (C) Form III.
Fig. 3 e Representative powder dissolution profiles of agomelatine polymorphs in 0.1MHCl. B: Form I,:: Form II,-: Form III.
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Table 1 e Intrinsic dissolution rates and solubilities of
agomelatine polymorphs in 0.1 N HCl at 37 C.
IDR (mg/cm2/min) Observed
maximum
concentration
(mg/ml)
Estimated
solubility
(mg/ml)Initial-
phase
Second-
phase
Form I 76.62 53.91 550 564
Form II 46.19 46.19 340 e
Form III 91.10 67.73 622 670
Fig. 4 e (A) XRPD patterns of agomelatine powder. (a) initial Form
II powder dispersed in 0.1 M HCl for 72 h, (d) initial Form II, (e) F
Form III. (B) XRPD patterns of the surface of agomelatine pellet.
Form II pellet in 0.1 M HCl after 3 h, (d) initial Form II, (e) Form
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appeared as typical convex dissolution curves, which indi-
cated both of them undergo the solvent-mediated phase
transformation (SMPT) from soluble forms to the less soluble
one during dissolution. The phase conversion from Form I and
Form III to Form II was subsequently confirmed by XRPD of the
residual solid phase collected after the dissolution test
(Fig. 4A), which showing that the residual solids of the two
soluble forms after powder dispersed were different from the
initial physical state of each form. The solvent-mediated
phase transformation of the polymorphic forms has been re-
ported to minimize the drug solubility and bioavailability. YetI, (b) Form I powder dispersed in 0.1 M HCl for 72 h, (c) Form
orm III powder dispersed in 0.1 M HCl for 72 h and (f) initial
(a) initial Form I, (b) Form I pellet in 0.1 M HCl after 3 h, (c)
III pellet in 0.1 M HCl after 3 h and (f) initial Form III.
a s i a n j o u rn a l o f p h a rm a c e u t i c a l s c i e n c e s 8 ( 2 0 1 3 ) 1 8 1e1 9 0 187the effect of the phase transformation of agomelatine forms
on in-vivo bioavailability needs further investigation.
The phase transformation was evidently observed in the
powder dissolution curves because during the powder disso-
lution test the sample were suspended as a large number of
small particles with tremendous surface area where the
transformation occurred. Yet this method is not suitable to
the quantitative treatment because the surface area was
scarcely obtained. On the other hand, the stationary disk
method with identical surface area is suitable for the quanti-
tative estimation of the phase transition point and the solu-
bility of metastable forms. When the solvent-mediated phase
transformation occurs, the crystallization of a less soluble
form would result in a decrease of the intrinsic dissolution
rate, which can be observed by the change of slope in the
dissolution profile [11e13,18e20]. In generally, the phase
transition point can be determined according to the turning
point on the DIDR curves. In addition, the estimated solubil-
ities of metastable forms can be calculated by the slope of the
initial part of the curve before the transformation occurs.
For this reason, the disc intrinsic dissolution test was
conducted for quantitative analysis.
3.2.2. Disc intrinsic dissolution rate (DIDR)
Intrinsic dissolution patterns of agomelatine polymorphs
were shown in Fig. 5. Good linearity between time and
released amount per unit area was found for Form II (the
linear regression equation was Y ¼ 46.19X, r ¼ 0.9995). How-
ever, decreases in the slopes were observed for the profiles of
Form I and Form III, which was an indication of phase trans-
formations. Surface of the drug pellets at the end of theFig. 5 e Representative intrinsic dissolutionprofiles of agomelatindissolution experiment was characterized by XRPD and the
results showed that there was no change of the XRPD pattern
for Form II, but both Form I and Form III transformed to Form II
as the characteristic diffraction peaks at 2q ¼ 18.58 and 22.04
of Form II were observed in the XRPD pattern of Form I and
Form III (Fig. 4B). These findings were in accordance with the
powder dissolution results.
For further quantitative analysis, segmentation of the DIDR
curves of Form I and Form III was obtained by splitting the
data in such a way that the linear regression lines for each
segment have the best correlation coefficient. The segmented
graphs were also presented in Fig. 5. It can be seen that the
turning point on the DIDR curves (phase transition point)
differed from that of the two forms (around 62 and 45 min for
Form I and Form III, respectively), which indicated that the
rate of transformation from Form III to Form II was faster than
that of Form I. The differences in the slopes measured from
the segments are presented Table 1. Intrinsic dissolution rates
(IDR) of Form I and Form III, which were calculated from the
initial slope of each form (the linear regression equation was
Y ¼ 76.12X, r ¼ 0.9987 for Form I and Y ¼ 91.10X, r ¼ 0.9996 for
Form III), were 76.62 and 91.10 mg/cm2/min, respectively, and
were approximately 2-fold and 1.7-fold compared with the
value of Form II.
Under sink conditions, the intrinsic dissolution rate of a
solid is given by:
IDR ¼ kCs (1)
where k is the intrinsic dissolution rate constant, and k ¼ D/h,
where D is the diffusivity of the solid and h is the thickness of
the diffusion layer, which depends on the geometry of thee polymorphs in0.1MHCl.-: Form III,B: Form I,:: Form II.
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ditions were controlled to have an identical numerical value,
the intrinsic dissolution rate constants of agomelatine poly-
morphs must be equal and the Eq. (1) leads to
IDRI=IDRII ¼ CI=CII (2)
where IDRⅠ and IDRII are the mass flux (mg/cm
2/min) for FormⅠ
and Form II, respectively, CⅠ and CII represent solubility (mg/ml)
of each form, respectively [20,21].
During the intrinsic dissolution of Form II, the dissolution
profiles exhibited the characteristic linear shape without
segmentation and no phase transformation was observed
(Fig. 5). Consequently, the maximum concentration
measured by the powder dispersed method (described in
Section 3.2.1) represented its equilibrium solubility. As for
Form I and Form III which were metastable forms during the
dissolution tests, the solubilities could be calculated accord-
ing to the above equations by using the solubility of Form II
and the IDR of each form. The calculated results were listed
in Table 1. The estimated solubilities were ranked as Form
III > Form I > Form II, which accorded with the results ob-
tained from the powder dissolution method. However, the
estimated solubilities of Form I and Form III were higher than
the experimentally observed maximum concentration value,
since SMPT took place during the powder dispersed
experiments.
The considerable differences in the dissolution behaviors
among agomelatine polymorphic forms were observed by
using two different dissolution methods, indicating that itFig. 6 e Mean plasma concentration-time curves of agomelatine
tablet with the dose of 6.8 mg/kg under fasting conditions（memay result in differences in the oral bioavailability. In addi-
tion, as the phase transformation between agomelatine
polymorphisms has been confirmed in-vitro, it might also
occur in-vivo and minimize the solubility which directly
related to the in-vivo absorption. Such assumptions were
tested by performing the pharmacokinetic study.
3.3. Pharmacokinetic study in dogs
The mean plasma concentration versus time profiles and
main pharmacokinetic parameters of agomelatine poly-
morphs after oral administration on dogs under fasted con-
ditions was presented in Fig. 6 and Table 2, respectively.
Statistically significant differences were observed among
the three forms of agomelatine in their plasma
concentration-time curves and pharmacokinetic parameters.
The AUC of the three forms was in the order of Form
III > Form I > Form II. This finding was consistent with the
results of the above dissolution rate tests, suggesting that the
dissolution property of agomelatine polymorphs might have
an impact on their plasma concentration. The plasma con-
centration level of Form III was the highest among the three
forms with the mean Cmax being 217.56 ng/ml, which reached
1.33 h (Tmax), which was similar to that of Form I. Compared
with Form II, the Cmax of Form III was approximately twice
higher and the absorption rate constant (ka) was 1.3 times
higher. On the other hand, the elimination rate constant
showed no statistically significant difference among the
three forms.polymorphs in beagle dog plasma following single oral of
an ± SD, n [ 6）.-: Form III, B: Form I, :: Form II.
Table 2 e Pharmacokinetic parameters of agomelatine
polymorphs (n[ 6, mean ± SD).
Pharmacokinetic
parameter
Form I Form II Form III
Tmax (h) 1.73  0.15a 1.83  0.19a 1.33  0.27b
Cmax (ng/ml) 194.17  34.86a 105.22  28.72b 217.56  57.06a
ka (1/h) 0.58  0.11a 0.34  0.05b 0.74  0.07c
t1/2 (h) 2.27  0.26 2.48  0.19 2.10  0.11
AUC0e12 h
(ng*h/ml)
296.25  49.39a 186.05  45.93b 331.16  54.74a
AUC0eN
(ng*h/ml)
309.62  52.08a 215.77  43.61b 358.77  56.97a
Different superscript letters indicate significant differences among
the means (P < 0.05).
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lowest IDR and solubility among the three forms while the
similarity in the oral bioavailability of Form I and Form III
should be attributed to the minor difference between their
IDRs. Although Form I and Form III both underwent solvent-
mediated phase transformation to Form II, the trans-
formation rates were relatively slow. Thus, the effects of
dissolution difference on the oral bioavailability can over-
shadow the effects of the phase transformation.3.4. In-vitro in-vivo correlation (IVIVC) analysis
In order to better understand the in-vitro in-vivo correlation
between agomelatine polymorphs, we tried to establish the
relationship between the IDRs and in-vivo pharmacokinetic
parameters.
As shown in Table 3, good linearity between the IDR and
the absorption rate constant (ka) was found for the three
forms, which suggested that the IDR is predictive to estimate
the in-vivo absorption rate of agomelatine polymorphs. For
the extent of absorption, good correlations was also found
between the IDR and AUC0e12 h.
DIDR is a rate phenomenon and as such correlates more
closely with in-vivo absorption behavior than the solubility,
which is an equilibrium phenomenon [13]. Kaplan suggested
that the IDR values below 1.0 mg/cm2/min indicated dissolu-
tion rate-limiting absorption [22]. According to Kaplan’s clas-
sification, Form I, Form II and Form III of agomelatine belonged
to the category of dissolution rate-limited drugs. This
assumption was supported by the above experiment results.
By performing the in-vitro in-vivo correlation analysis, the
intrinsic dissolution test was confirmed to be predictive for
relative bioavailability estimation of agomelatine forms and
could be used as an in-vitro screening tool for predicting in-
vivo performance of polymorphisms.Table 3 e The linear in-vitro/in-vivo correlations of
agomelatine polymorphisms.
In-vivo parameter Equation r
ka Y ¼ 0.0087X  0.0706 0.9962
AUC0e12 h Y ¼ 3.2912X þ 36.4785 0.99604. Conclusion
In summary, selecting a polymorph with desirable physico-
chemical properties is important during the development of
polymorphic drugs. Among the three forms of agomelatine in
this study, Form III exhibited superior dissolution properties
but defects in the stability while Form II was just the opposite.
Improvement of solubility of Form II by co-crystallization or
other methods have been reported in some literature. On the
other hand,wemight expect increasing stability ofmetastable
forms in the future research (this step may require extra
necessary excipients, surfactant, or other methods), and all of
this will contribute to the full use of agomelatine polymorphs.Acknowledgments
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